Jefferies Group LLC reissued their buy rating on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a research note released on Friday, July 14th. The brokerage currently has a $26.00 price objective on the biotechnology company’s stock.
Other research analysts also recently issued reports about the company. Cowen and Company restated a buy rating and set a $40.00 price target on shares of Heron Therapeutics in a report on Friday, May 26th. Noble Financial restated a buy rating on shares of Heron Therapeutics in a report on Friday, May 12th. Cantor Fitzgerald restated a buy rating and set a $31.00 price target (up previously from $30.00) on shares of Heron Therapeutics in a report on Thursday, May 11th. Aegis reiterated a buy rating on shares of Heron Therapeutics in a research note on Tuesday, March 21st. Finally, Zacks Investment Research upgraded Heron Therapeutics from a hold rating to a buy rating and set a $14.00 target price on the stock in a research note on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $31.00.
Shares of Heron Therapeutics (NASDAQ HRTX) opened at 15.85 on Friday. The company’s 50 day moving average is $15.24 and its 200-day moving average is $14.47. Heron Therapeutics has a one year low of $12.21 and a one year high of $24.00.
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.06. The company had revenue of $3.63 million during the quarter, compared to the consensus estimate of $1.96 million. Equities research analysts forecast that Heron Therapeutics will post ($3.72) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was reported by BBNS and is the sole property of of BBNS. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://baseballnewssource.com/markets/heron-therapeutics-hrtx-buy-rating-reaffirmed-at-jefferies-group-llc-updated-updated-updated/1199721.html.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Airain ltd bought a new position in shares of Heron Therapeutics during the second quarter valued at $442,000. Royce & Associates LP bought a new position in shares of Heron Therapeutics during the second quarter valued at $796,000. Legal & General Group Plc boosted its position in shares of Heron Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 2,383 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Heron Therapeutics by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock valued at $2,837,000 after buying an additional 14,086 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in shares of Heron Therapeutics during the second quarter valued at approximately $457,000.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with our FREE daily email newsletter.